Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death

Molecular Cancer Therapeutics

Volumn 8, Issue 8, 2009, Pages 2183-2192

  Pritchard, Justin R ^a   Cosgrove, Benjamin D ^b   Hemann, Michael T ^a   Griffith, Linda G ^b   Wands, Jack R ^c   Lauffenburger, Douglas A ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; I KAPPA B KINASE; PROTEIN KINASE B; STAT3 PROTEIN; TANESPIMYCIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL;

APOPTOSIS; BENZOQUINONES; CARCINOMA, HEPATOCELLULAR; CELL DEATH; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; HUMANS; LACTAMS, MACROCYCLIC; LIVER NEOPLASMS; PRINCIPAL COMPONENT ANALYSIS; PROTEIN KINASE INHIBITORS;

EID: 68849117407     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1203     Document Type: Article

References (28)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
2. Chabner BA, Roberts TG, Jr. Chemotherapy and the war on cancer. Nat Rev Cancer 2005;5:65-71.
3. Petrelli A, Giordano S. From single to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008;15:422-32.
4. Uehara Y, Makoto H, Tomio T, Umezawa H. Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol Cell Biol 1986;6:2198-206.
5. Whitesell L, Lindquist S. Hsp90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
6. Whitesell L, Shifrin SD, Schwab G, Neckers L. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res 1992;52:1721-8.
7. Zhao R, Davey M, Hsu YC, et al. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the Hsp90 chaperone. Cell 2005;120:715-27.
8. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-10.
9. Hostein I, Robertson D, DiStefano F, et al. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001;61:4003-9.
10. Bareng J, Jilani I, Gorre M, et al. A potential role for Hsp90 inhibitors in the treatment of Jak2 mutant-positive diseases as demonstrated using quantitative flow cytometry. Leuk Lymphoma 2007;48:2189-95.
11. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006;107:1092-100.
12. 2/M arrest in glioblastoma cell lines. Oncogene 2007;26:7185-93.
13. Solit DB, Ivy SP, Kopli C, et al. Phase 1 trial of 17-allyamino-17- demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007;13:1775-82.
14. Chandarlapaty S, Sawai A, Qing Y, et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 2008;14:240-8.
15. Yun BG, Matts R. Hsp90 functions to balance the phosphorylation state of Akt during C2C12 myoblast differentiation. Cell Signal 2005;17:1477-85.
16. Donze O, Abbas-Terki T, Picard D. The Hsp90 chaperone is both a facilitator and a repressor of the dsRNA-dependent kinase PKR. EMBO J 2001;20:3771-80.
17. Koga F, Xu W, Karpova TS, et al. Hsp90 inhibition transiently activates Src and promotes Src-dependent Akt and Erk activation. Proc Natl Acad Sci U S A 2006;103:11318-22.
18. Kumar N, Afeyan R, Kim HD, Lauffenburger DA. A multi-pathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells. Mol Pharmacol 2008;73:1668-78.
19. Janes KA, Yaffe MB. Data-driven modeling of signal-transduction networks. Nat Rev Mol Cell Biol 2006;7:820-8.
20. Lee HC, Tian B, Sedivy J, Wands JR, Kim M. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterol 2006;131:1208-17.
21. Jolliffe IT. Principal components analysis. 2nd ed. New York: Springer-Verlag; 2002.
22. Eriksson L, Johansson E, Kettanel N, Wold S. Multi- and megavariate data analysis, principles and applications. Umeå (Sweden): Umetrics AB; 2001.
23. Mardia KV, Kent JT, Bibby JM. Multivariate analysis. New York: Academic Press; 1979.
24. Miller-Jensen K, Janes KA, Brugge JS, Lauffenburger DA. Common effector processing mediates cell-specific responses to stimuli. Nature 2007;448:604-8.
25. Kemp ML, Wille L, Lewis CL, Nicholson LB, Lauffenburger DA. Quantitative network signal combinations downstream of TCR activation can predict IL-2 production response. J Immunol 2007;178:4984-92.
26. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32.
27. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
28. Pedranzini L, Dechow T, Berishaj M, et al. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res 2006;66:9714-21.